Novo Nordisk A/S Stock News

The stock move comes as Novo Nordisk, maker of obesity drug Wegovy, overtook Tesla's market value Thursday.

Novo Nordisk's CEO on Friday said compounded semaglutide in the United States is a serious health issue.

Wegovy obesity drug maker Novo Nordisk surpassed Tesla in market value Thursday after fresh early trial data showed positive results for its new experimental weight loss pill.

Novo Nordisk will prioritise acquisitions that can complement its pipeline of obesity and diabetes drugs rather than buying supply chain companies, the Danish group's head of business development told

Novo Nordisk's head of development on Friday told Reuters he was very comfortable the drugmaker would be able to launch the pill version of its experimental weight loss drug amycretin this decade.

Novo Nordisk (NYSE:NVO)'s shares are significantly overvalued, based on analysis shared by the American bank Jefferies in a note to clients. It said that, as ever, Novo delivered its 'usual polished p

Novo Nordisk (NVO) shares opened at an all-time high after a promising weight loss trial. Jeff Pierce discusses this as Eli Lilly (LLY) shares fall after Novo Nordisk's weight loss trial shows positiv

Novo's shares have risen more than three-fold since June 2021 when it launched Wegovy in the US, last year becoming Europe's most valuable listed company, ahead of LVMH.

Novo Nordisk revealed results from a phase 1 study of amycretin at an investor event on Thursday. Patients taking the experimental drug achieved an average weight loss of 13.1% after 12 weeks.

Shares of Novo Nordisk (NVO) have hit a record high on phase 1 trial data from Amycretin, its latest weight loss product. The new drug shows over 13% weight loss in users after 12 weeks of use, more t

Novo Nordisk said on Thursday it expects Wegovy to be approved for sale in China this year and plans to soon launch the popular weight-loss drug in the largest Asian market with capped volumes.

Novo Nordisk's global obesity drug rollout will be dominated by its injectable medicines, while its oral version will be introduced later in higher priced markets, the company's Chief Executive Lars F

Novo Nordisk A/S (NYSE:NVO) stock is gapping to record highs today, after the pharmaceutical company reported positive phase 1 trial results for its experimental weight-loss drug, amycretin.

The company said its new treatment for weight loss, called Amycretin, appeared even more effective than its popular Wegovy drug in trials.

The American depositary receipts (ADRs) of Novo Nordisk A/S (NVO) gained more than 8% in early trading Thursday after the Danish maker of Ozempic and Wegovy released promising data on an experimenta